Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
The Role of Amyloid in Neurological Disorders
share announcement

The Role of Amyloid in Neurological Disorders

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Biomacromolecules: Proteins".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1179

Special Issue Editors

Dr. Marny Fedrigo

E-Mail Website
Guest Editor
Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, 35128 Padua, Italy
Interests: heart and kidney transplantation; antibody mediated rejection; complement and DSA antibody; vasculitis; biomarkers mRNA; miRNA; systemic and cardiac amyloidosis; congenital heart diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Tamara Berno

E-Mail Website
Guest Editor
Hematology Unit, Department of Medicine, Hospital University of Padua, Padova, Italy
Interests: plasma cell dyscrasias in particular multiple myeloma; AL amyloidosis

Special Issue Information

Dear Colleagues,

Interest in extracellular deposits of amorphous protein in the central and peripheral neurological system is growing due to new therapeutic strategies that could improve patients’ survival and quality of life. Amyloid-beta continues to be a most important diagnostic and prognostic issue for Alzheimer's disease (AD) and other neurological disorders. Neuropathy is a common manifestation of both hereditary and acquired forms of systemic amyloidosis and may present with progressive sensorimotor polyneuropathy, focal neuropathy, autonomic neuropathy, and other unusual clinical presentations.

Many aspects have been defined in several papers published; that said, there are many others aspects still to be understood. In particular, we do not yet know how the process of this degenerative disease starts, nor do we understand its mechanisms of progression.

This Special Issue aims to collate expertise on neurological disorders due to amyloid protein; in doing so, it will clarify the role of amyloid in the central and peripheral nervous system and its relationship with the immune system. Novel developments in terms of therapeutic options involving proteins, peptides, and antibodies will also be described.

Dr. Marny Fedrigo
Dr. Tamara Berno
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • amyloid-beta
  • neurodegenerative disorders
  • aducanumab
  • oligomers
  • cross-amyloid intraction

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 2836 KiB  
Article
Uptake of 18F-AV45 in the Putamen Provides Additional Insights into Alzheimer’s Disease beyond the Cortex
by Zhengshi Yang, Jefferson W. Kinney, Dietmar Cordes and The Alzheimer’s Disease Neuroimaging Initiative
Biomolecules 2024, 14(2), 157; https://0-doi-org.brum.beds.ac.uk/10.3390/biom14020157 - 29 Jan 2024
Viewed by 949
Abstract
Cortical uptake in brain amyloid positron emission tomography (PET) is increasingly used for the biological diagnosis of Alzheimer’s disease (AD); however, the clinical and biological relevance of the striatum beyond the cortex in amyloid PET scans remains unclear. A total of 513 amyloid-positive [...] Read more.
Cortical uptake in brain amyloid positron emission tomography (PET) is increasingly used for the biological diagnosis of Alzheimer’s disease (AD); however, the clinical and biological relevance of the striatum beyond the cortex in amyloid PET scans remains unclear. A total of 513 amyloid-positive participants having 18F-AV45 amyloid PET scans available were included in the analysis. The associations between cognitive scores and striatal uptake were analyzed. The participants were categorized into three groups based on the residual from the linear fitting between 18F-AV45 uptake in the putamen and the cortex in the order of HighP > MidP > LowP group. We then examined the differences between these three groups in terms of clinical diagnosis, APOE genotype, CSF phosphorylated tau (ptau) concentration, hippocampal volume, entorhinal thickness, and cognitive decline rate to evaluate the additional insights provided by the putamen beyond the cortex. The 18F-AV45 uptake in the putamen was more strongly associated with ADAS-cog13 and MoCA scores (p < 0.001) compared to the uptake in the caudate nucleus. Despite comparable cortical uptakes, the HighP group had a two-fold higher risk of being ε4-homozygous or diagnosed with AD dementia compared to the LowP group. These three groups had significantly different CSF ptau concentration, hippocampal volume, entorhinal thickness, and cognitive decline rate. These findings suggest that the assessment of 18F-AV45 uptake in the putamen is of unique value for evaluating disease severity and predicting disease progression. Full article
(This article belongs to the Special Issue The Role of Amyloid in Neurological Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop